Estonia In Vitro Diagnostics (IVD) Market: by Technology (Molecular Diagnostics (Hepatitis C, Hepatitis B, Human Immunodeficiency Virus (HIV), Cytomegalovirus (CMV), Epstein–Barr Virus (EBV), Tuberculosis, Sexually Transmitted Diseases (STDs), Hospital Acquired Infections, Respiratory Infections, Human Papillomavirus (HPV), Covid- 19)), Tissue Diagnostics (H&E Stains, Special Stains, Advanced Stains, Digital Scanners), Sequencing (Clinical, NIPT, and Research Use Only), Country (Estonia,), and forecast to 2029

Purchase Option

$ 3100
$ 4600
$ 6900

Estonia In Vitro Diagnostics (IVD) Market size was valued at Euro 20.9 million in 2022 and is poised to grow at a significant CAGR of 3.5% from 2022–2028. The Estonia in-vitro diagnostics (IVD) market is a dynamic and rapidly evolving sector within the healthcare industry. IVD refers to medical devices and diagnostic techniques that are used to analyze samples derived from the human body, such as blood, urine, and tissue, outside the body. These tests provide crucial information for the early detection, diagnosis, and management of diseases and conditions. Molecular diagnostics in IVD market are growing at fastest rate due to increasing prevalence of various diseases such as Hepatitis B and C, Human Immunodeficiency Virus (HIV), Cytomegalovirus (CMV), Epstein–Barr virus (EBV), Tuberculosis, Sexually Transmitted Diseases (STDs), Hospital Acquired Infections, Respiratory Infections, Human Papillomavirus (HPV) and Covid- 19. Hospital Acquired Infections (HAI) represent a major clinical, epidemiologic, and economic problem because they are linked to high morbidity and mortality rates and hospitalization costs. In 2022, hospital-acquired infections accounted for highest market value of 690.4 thousand Euros in molecular diagnostics and are expected to reach 704.9 thousand Euros by 2029. Tissue diagnostics testing continues to serve as one of the gold standards for cancer diagnosis. The type of cancer, the stage, and the extent to which the disease has infiltrated healthy tissue may all be diagnosed via a biopsy. In 2021, Tissue Diagnostics accounted for a market the value of 1.2 Mn Euro and is expected to reach 2.2 Mn Euro by 2029. Estonia is 17 years into its long-term genome sequencing program. The samples are stored in a repository, the Estonian Genome Centre, based in the University of Tartu. As a part of its National Personalized Medicine program in Estonia, from 2018 they carried out a project to recruit and genotype 100,000 new biobank participants. In Estonia, majority of NIPT samples are analyzed on Illumina device.

Estonia In Vitro Diagnostics Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

3.5%

Largest Market

N/A

Fastest Growing Market

N/A
Estonia In Vitro Diagnostics (IVD) Market Dynamics

In Estonia, high growth areas in infectious diseases are HPV, STDs, HIV, Respiratory Infections, Hospital Acquired infections (HAIs). Tissue diagnostics and sequencing in Estonia IVD market also accounted for the high market value. The prevalence of various diseases and investment in healthcare infrastructure are driving market growth. Human papillomavirus (HPV) is a prevalent sexually transmitted infection (STI) linked to cervical cancer. The increasing awareness about the importance of HPV vaccination and its effectiveness in preventing cervical cancer has led to a higher demand for screening and diagnostic tests for HPV in Estonia. The incidence of sexually transmitted diseases (STDs) has been on the rise globally, including in Estonia. Factors such as changing sexual behaviors, inadequate prevention measures, and increased testing and awareness programs have contributed to the higher detection and diagnosis rates of STDs, driving the growth of the Estonia IVD market. Estonia's healthcare infrastructure, particularly in rural areas, may be limited compared to urban centers. The availability and accessibility of advanced diagnostic tools and technologies may be restricted, hindering the estonia IVD market growth. Financial constraints within the healthcare system can limit investment in advanced diagnostic technologies.

Estonia In Vitro Diagnostics Market Segmentation

By Technology
  • Molecular Diagnostics
    • Hepatitis B
    • Hepatitis C
    • Human Immunodeficiency Virus (HIV)
    • Cytomegalovirus (CMV)
    • Epstein–Barr virus (EBV)
    • Tuberculosis
    • Sexually Transmitted Diseases (STDs)
    • Hospital Acquired Infections
    • Respiratory Infections
    • Human Papillomavirus (HPV)
    • Covid- 19
By Technology
  • Tissue Diagnostics
    • H&E Stains
    • Special Stains
    • Advanced Stains
    • Digital Scanners
By Technology
  • Sequencing
    • Clinical
    • NIPT
    • Research Use Only

Frequently Asked Questions

The Estonia IVD market is valued at Euro 20.9 million in 2022 and is poised to grow at a significant CAGR of 3.5% over 2023–2028.

QIAGEN, Bio-Rad Laboratories, Roche Diagnostics, Thermofisher Scientific, Cepheid, Inc., Abbott, Inc., Seegene, Inc., Illumina, Inc., Dako, Merck, Leica and Abbott.

Hospital-acquired infection is accounted for 690.4 thousand Euros in 2021 and expected to reach 704.9 thousand Euros by 2029. HIV is the second highest disease accounting for 411,4 thousand Euros and is expected to reach 440.1 thousand Euro by 2029

Molecular diagnostics technology is expected to drive the market growth as it is required for various diseases. Tissue Diagnostics accounted for the 2nd highest market value of expected to reach 2,223,85 Euro by 2029.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018-2022), and forecast (2023-2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • QIAGEN
  • Bio-Rad Laboratories
  • Roche Diagnostics
  • Thermofisher Scientific
  • Cepheid, Inc.
  • Abbott, Inc.
  • Illumina, Inc.
  • Twist Bioscience
  • Dako
  • Leica
  • Abbott
  • Merck

Adjacent Markets